Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

Robert Chapman, Loretta Itri, Richard Gralla, David Kelsen, Ephraim Casper, Robert Golbey

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

Original languageEnglish (US)
Pages (from-to)205-207
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number2-3
StatePublished - Apr 1982
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this